Open AccessElagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
Author(s) -
James A. Simon,
Ayman AlHendy,
David F. Archer,
Kurt Barnhart,
Linda D. Bradley,
Bruce R. Carr,
Thomas Dayspring,
Eve C. Feinberg,
Veronica Gillispie,
Sandra Hurtado,
Jin Hee Kim,
Ran Liu,
Charlotte D. Owens,
Ozgul Muneyyirci-Delale,
Alice Wang,
Nelson B. Watts,
William D. Schlaff
Publication year - 2020
Publication title -
obstetrics and gynecology (new york. 1953. online)/obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 1873-233X
pISSN - 0029-7844
DOI - 10.1097/aog.0000000000003869
Subject(s) - medicine , discontinuation , adverse effect , clinical endpoint , menstrual bleeding , menstrual cycle , gynecology , obstetrics , hormone , randomized controlled trial
To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas.